ArticleVaccines2025

Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign.

Pablo Estrella-Porter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.